Patent ID: 8663639
Filing Date: 2014-03-04
Classification: A61K,A61P

Abstract:
1. A method for treating wet age-related macular degeneration in a human subject by repeated administration of a first formulation and a second formulation, the method comprising: (a) administering to the human subject two or more doses of a volume of the first formulation by intravitreal placement, wherein the volume of the first formulation comprises an amount of and about 500 μg of ranibizumab; and (b) administering to the human subject two or more doses of a volume of the second formulation by intravitreal or subconjuctival placement, wherein the volume of the second formulation comprises an amount of between about 200 μg and about 2000 μg of rapamycin, or a pharmaceutically acceptable salt or ester thereof; wherein the administration of rapamycin or a pharmaceutically acceptable salt or ester thereof decreases the frequency at which ranibizumab is administered to treat wet age-related macular degeneration in the human subject.